Two Biotech Stocks Are Just So Hot Right Now (Corbus Pharmaceuticals Holdings, Inc.)
On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>